Gemini nanoparticles as a co-delivery system for antigen - CpG oligodeoxynucleotide adjuvant combination

International Journal of Biomedical Nanoscience and Nanotechnology

Volumn 1, Issue 2-4, 2010, Pages 290-307

  Badea, Ildiko ^a   Babiuk, Shawn ^b,c   Babiuk, Lorne ^d   Foldvari, Marianna ^e  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b CANADIAN FOOD INSPECTION AGENCY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF WATERLOO   (Canada)

Author keywords

CpG ODNs; gemini surfactant; HEL; hen egg lysozyme; immune response; immunomodulation; intradermal delivery; nanoparticles; Th1 Th2 immune response; topical delivery; vaccine delivery

Indexed keywords

EID: 84863775126     PISSN: 17560799     EISSN: 17560802     Source Type: Journal    
DOI: 10.1504/IJBNN.2010.034656     Document Type: Article

References (35)

1. Alcon, V.L., Foldvari, M., Snider, M., Willson, P., Gomis, S., Hecker, R., Babiuk, L.A. and Baca-Estrada, M.E. (2003) ‘Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix)’, Vaccine, Vol. 21, Nos. 17–18, pp.1811–1814.
2. Baca-Estrada, M.E., Foldvari, M., Ewen, C., Badea, I. and Babiuk, L.A. (2000) ‘Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system’, Vaccine, Vol. 18, No. 17, pp.1847–1854.
3. Baca-Estrada, M.E., Foldvari, M., Snider, M., Van Drunen Littel-Van Den Hurk, S. and Babiuk, L.A. (1997) ‘Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D’, Vaccine, Vol. 15, No. 16, pp.1753–1760.
4. Badea, I., Verrall, R., Baca-Estrada, M., Tikoo, S., Rosenberg, A., Kumar, P. and Foldvari, M. (2005) ‘In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes’, J. Gene. Med, Vol. 7, No. 9, pp.1200–1214.
5. Badea, I., Wettig, S., Verrall, R. and Foldvari, M. (2007) ‘Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice’, Eur. J. Pharm. Biopharm., Vol. 65, No. 3, pp.414–422.
6. Ballas, Z.K., Krieg, A.M., Warren, T., Rasmussen, W., Davis, H.L., Waldschmidt, M. and Weiner, G.J. (2001) ‘Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs’, J. Immunol., Vol. 167, No. 9, pp.4878–4886.
7. Beignon, A.S., Briand, J.P., Muller, S. and Partidos, C.D. (2002) ‘Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4 + T cells’, Immunology, Vol. 105, No. 2, pp.204–212.
8. Bliss, J., Van Cleave, V., Murray, K., Wiencis, A., Ketchum, M., Maylor, R., Haire, T., Resmini, C., Abbas, A.K. and Wolf, S.F. (1996) ‘IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T’, J. Immunol., Vol. 156, No. 3, pp.887–894.
9. Chikh, G., De Jong, S.D., Sekirov, L., Raney, S.G., Kazem, M., Wilson, K.D., Cullis, P.R., Dutz, J.P. and Tam, Y.K. (2009) ‘Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles’, International Immunology, Vol. 21, No. 7, pp.757–767.
10. Chu, R.S., Targoni, O.S., Krieg, A.M., Lehmann, P.V. and Harding, C.V. (1997) ‘CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity’, J. Exp. Med, Vol. 186, No. 10, pp.1623–1631.
11. Coeshott, C.M., Smithson, S.L., Verderber, E., Samaniego, A., Blonder, J.M., Rosenthal, G.J. and Westerink, M.A. (2004) ‘Pluronic F127-based systemic vaccine delivery systems’, Vaccine, Vol. 22, No. 19, pp.2396–2405.
12. Diwan, M., Tafaghodi, M. and Samuel, J. (2002) ‘Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres’, J. Control Release, Vol. 85, Nos. 1–3, pp.247–262.
13. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K. and Akira, S. (2000) ‘A toll-like receptor recognizes bacterial DNA’, Nature, Vol. 408, No. 6813, pp.740–745.
14. Hsieh, C.S., Macatonia, S.E., O’garra, A. and Murphy, K.M. (1995) ‘T cell genetic background determines default T helper phenotype development in vitro’, J. Exp. Med., Vol. 181, No. 2, pp.713–721.
15. Huang, L., Krieg, A.M., Eller, N. and Scott, D.E. (1999) ‘Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria’, Infect Immun., Vol. 67, No. 12, pp.6257–6263.
16. Jakob, T., Walker, P.S., Krieg, A.M., Von Stebut, E., Udey, M.C. and Vogel, J.C. (1999) ‘Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses’, Int. Arch Allergy Immunol., Vol. 118, Nos. 2–4, pp.457–461.
17. Klinman, D.M., Yi, A.K., Beaucage, S.L., Conover, J. and Krieg, A.M. (1996) ‘CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma’, Proc. Natl. Acad. Sci. USA, Vol. 93, No. 7, pp.2879–2883.
18. Krieg, A.M. (2002) ‘CpG motifs in bacterial DNA and their immune effects’, Annu. Rev. Immunol., Vol. 20, pp.709–760.
19. Krieg, A.M., Yi, A.K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A. and Klinman, D.M. (1995) ‘CpG motifs in bacterial DNA trigger direct B-cell activation’, Nature, Vol. 374, No. 6522, pp.546–549.
20. Krishnamachari, Y. and Salem, A.K. (2009) ‘Innovative strategies for co-delivering antigens and CpG oligonucleotides’, Adv. Drug Deliv. Rev, Vol. 61, No. 3, pp.205–217.
21. Kwon, Y.J., Standley, S.M., Goh, S.L. and Frechet, J.M. (2005) ‘Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles’, J. Control Release, Vol. 105, No. 3, pp.199–212.
22. Marinaro, M., Boyaka, P.N., Jackson, R.J., Finkelman, F.D., Kiyono, H., Jirillo, E. and Mcghee, J.R. (1999) ‘Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin’, J. Immunol., Vol. 162, No. 1, pp.114–121.
23. Menger, F.M. and Keiper, J.S. (2000) ‘Gemini surfactants’, Angew Chem. Int. Ed. Engl., Vol. 39, No. 11, pp.1906–1920.
24. Rosenzweig, H.S., Rakhmanova, V.A. and Macdonald, R.C. (2001) ‘Diquaternary ammonium compounds as transfection agents’, Bioconjug. Chem., Vol. 12, No. 2, pp.258–263.
25. Scheule, R.K. (2000) ‘The role of CpG motifs in immunostimulation and gene therapy’, Adv. Drug Deliv. Rev, Vol. 44, Nos. 2–3, pp.119–134.
26. Singh, M., Kazzaz, J., Chesko, J., Soenawan, E., Ugozzoli, M., Giuliani, M., Pizza, M., Rappouli, R. and O’hagan, D.T. (2004) ‘Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B’, J. Pharm. Sci., Vol. 93, No. 2, pp.273–282.
27. Singh, M., Ott, G., Kazzaz, J., Ugozzoli, M., Briones, M., Donnelly, J. and O’hagan, D.T. (2001) ‘Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA’, Pharm. Res., Vol. 18, No. 10, pp.1476–1479.
28. Tighe, H., Takabayashi, K., Schwartz, D., Van Nest, G., Tuck, S., Eiden, J. J., Kagey-Sobotka, A., Creticos, P.S., Lichtenstein, L.M., Spiegelberg, H.L. and Raz, E. (2000) ‘Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity’, J. Allergy Clin. Immunol., Vol. 106, No. 1, Pt. 1, pp.124–134.
29. Wettig, S.D., Verrall, R.E. and Foldvari, M. (2008) ‘Gemini surfactants: a new family of building blocks for non-viral gene delivery systems’, Current Gene Therapy, Vol. 8, No. 1, pp.9–23.
30. Wilson, K.D., De Jong, S.D., Kazem, M., Lall, R., Hope, M.J., Cullis, P.R. and Tam, Y.K. (2009a) ‘The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine’, J. Gene. Med., Vol. 11, No. 1, pp.14–25.
31. Wilson, K.D., De Jong, S.D. and Tam, Y.K. (2009b) ‘Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy’, Adv. Drug Deliv. Rev., Vol. 61, No. 3, pp.233–242.
32. Yi, A.K. and Krieg, A.M. (1998) ‘CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel’, J. Immunol., Vol. 160, No. 3, pp.1240–1245.
33. Yi, A.K., Klinman, D.M., Martin, T.L., Matson, S. and Krieg, A.M. (1996) ‘Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway’, J. Immunol., Vol. 157, No. 12, pp.5394–5402.
34. Zana, R. (2002) ‘Dimeric (gemini) surfactants: effect of the spacer group on the association behavior in aqueous solution’, Journal of Colloid and Interface Science, Vol. 248, No. 2, pp.203–220.
35. Zhang, X.Q., Dahle, C.E., Weiner, G.J. and Salem, A.K. (2007) ‘A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles’, J. Pharm. Sci., Vol. 96, No. 12, pp.3283–3292.